Diagnosis & Therapy
COVID-19 crisis changed treatment for most lung cancer patients
At a cancer treatment center that tracked data prospectively, the COVID-19 epidemic led directly to treatment delays and reduced surveillance in the majority of patients being treated for lung cancer, according to recently published data.
Lung cancer screening model identifies more at-risk African Americans
A new model for lung cancer screening may ensure that African Americans at risk for lung cancer are no longer undercounted, according to researchers.
Treatment landscape changes but challenges persist for ROS1 or NTRK fusion–positive lung cancer
Patients with non–small cell lung cancer harboring ROS1 or NTRK fusions may face a particularly challenging journey. These cancers, while relatively rare, can be less responsive to conventional treatment, experts say, and may exhibit more aggressive behavior than cancers that are not gene fusion positive.
Adding durvalumab to EP for ES-SCLC improves overall survival
Adding durvalumab immunotherapy to etoposide and platinum (EP) for the first-line treatment for extensive-stage small cell lung cancer (ES-SCLC) significantly improved 18-month overall survival, compared with EP alone, in the phase 3 CASPIAN trial.
Maintenance immunotherapy fails in SCLC
Maintenance immunotherapy offers no added survival benefit in patients with extensive disease small cell lung cancer (ED-SCLC), according to results from the CheckMate 451 trial.
Checkpoint inhibitor shows efficacy in third line for SCLC
The immune checkpoint inhibitor pembrolizumab produced durable objective responses in some patients with extensive-stage small-cell lung cancer (SCLC) who had disease progression on two or more prior lines of therapy, data from two clinical trials showed.
New Approaches to Small Cell Lung Cancer Therapy
Small-cell lung cancer (SCLC) is an extremely aggressive pulmonary malignancy with 5-year overall survival rates of just 5% to 10% with conventional therapeutic regimens.
Clinical Trials Chip Away at Small-Cell Lung Cancer Defenses
Small-cell lung cancer (SCLC), in the words of one leading oncologist, is the “type of disease that gives cancer a bad name.”
Vaccine may restore NSCLC response to checkpoint inhibitors
BY CHRISTINE KILGORE MDedge News SAN FRANCISCO – An experimental allogeneic cellular vaccine combined with the checkpoint inhibitor nivolumab (Opdivo) may boost the immune response in patients with previously treated non–small cell lung cancer (NSCLC) tumors, results...
Neoadjuvant atezolizumab shrinks NSCLC tumors
BY CHRISTINE KILGORE MDedge News SAN FRANCISCO – One-fifth of patients with resectable non–small cell lung cancer had a major pathologic response to neoadjuvant therapy with the immune checkpoint inhibitor atezolizumab (Tecentriq), according to a preliminary analysis...
Interview with Roy S. Herbst, MD, PhD, on Immunotherapy in Lung Cancer
BY CHRISTINE KILGORE MDedge News Roy S. Herbst, MD, PhD, is the Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology at Yale University, and Chief of Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital in New Haven, Connecticut....
Cost And Coping
Diagnosis and Therapy